Publication | Closed Access

Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881

Breast OncologyOncologySingle TreatmentMedicineClinical TrialsLhrh-agonist BuserelinBreast CancerPharmacotherapyEortc Study 10881Cancer TreatmentPharmacologyRadiation OncologyCancer ResearchEndocrine-related CancerHealth Sciences